Long Position on ABEO @ $15.00 on 9/15/2017 (Momentum)

Abeona Therapeutics Inc. (ABEO) focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases.

The company's lead programs are ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV-based gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

In addition, the company is developing plasma-based protein therapy pipeline, including SDF Alpha, an alpha-1 protease inhibitor for inherited COPD using its proprietary salt diafiltration ethanol-free process.

Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB. 

Shares have formed a bullish "flag" after the company received FDA's "Breakthrough Therapy Designation" for its EB-101. “EB-101 is an autologous gene-corrected cell therapeutic approach that utilizes a patient’s own cells and genetically engineering them to produce the correct version of collagen, which helps hold skin on to the body, thereby reducing the number of painful blisters caused by injury and improving wound healing,” stated Timothy J. Miller, Ph.D., Abeona’s President and CEO.  Higher share prices are expected for this stock.

52-Weeks Trading Range: $4.05 - $15.25

Entry Point: $15.00

Stop Loss:  $14.25

Target Price: $16.70

Updates

9/18/2017 11:05:20 AM

ABEO closed at $17

Position closed on 9/18/2017 at price of $17.00 with a 13.33% gain in 3 days.

Back to Portfolio